German pharma, medtech and diagnostics travel on a strong reputation — GMP quality, engineering, “Made in Germany.” But every target market has its own version of the gap between allowed to sell and actually paid. The discipline that gets a foreign company into Germany is the same one that takes a German company out.
Taking a German product abroad follows a pattern that repeats across markets: pick the market and sequence, appoint the local representative that most regulated markets require, choose a legal structure, register with the local authority, clear pricing / health-economic hurdles, secure distribution and public procurement — and, increasingly, decide how much to localise, because many markets reward local production. Registration lets you sell; it rarely guarantees you're bought. It's the mirror of our German thesis: authorized isn't paid.
A company that knows how hard German market access is has already learned the key lesson — every serious market has a version of the same gap.
German life-sciences companies rarely lack a competitive product or credibility. What trips them up abroad is assuming the German playbook — or a pure export mindset — transfers. It doesn't: each market has its own regulator, its own reimbursement or procurement logic, and its own local-representation rules. Reading that market, and closing its gap, is a discipline — the same one, mirrored, that we apply into Germany.
Getting registered abroad is the easy part. Getting bought is the work — wherever you go.
The details differ by country; the sequence rarely does. Skip a step and it comes back to bite — usually at the procurement stage.
Which country first, and why — market size, reimbursement outlook, competitive position and how it opens the next market.
Most regulated markets require a local agent / authorised representative to deal with the regulator and carry pharmacovigilance — a load-bearing choice, not a formality.
Agent / distributor, an own local entity, or a joint venture / manufacturing footprint — the choice shapes tender and pricing access later.
The dossier, GMP evidence and product registration with the national regulator — the entry ticket to sell.
Reference pricing and, increasingly, mandatory economic-evaluation studies — value has to be demonstrated, not asserted.
Distributors, hospital and public tenders — where the actual revenue is won, often through a dominant national buyer.
Many markets reward local production with tender preference, incentives and faster approval — decide how deep to go.
The gap you know from Germany exists everywhere — it just wears a different name and mechanism. Recognising it early is the whole advantage.
Deep-dive market maps for the corridors German life-sciences companies ask about most — each with the structure, registration, pricing and localisation reality.
Legal vehicles, the FDI route, CDSCO licensing and the sequence — a structural map with a roadmap.
Read the India map →SFDA registration, the local-agent rule, and why NUPCO and Vision 2030 reward localisation.
Read the KSA map →Gulf, Asia and beyond — if your market isn't mapped yet, we'll build the roadmap for it.
Ask us →Knowing which parts of the playbook transfer, and which must be rebuilt per market, saves the most time.
Your GMP dossier and quality systems travel well; your German commercial and distribution playbook usually doesn't. Plan to reuse the substance and rebuild the go-to-market for each market.
German life-sciences companies carry advantages abroad that open doors faster than most.
The trap: assuming the reputation does the selling. It opens the door — local access still has to be won.
Start with a fixed, low-risk deliverable for your target market, then plan execution in a working session — the same model, whichever market you're headed to.
A one-off, written roadmap for your target market — structure, registration, pricing and the localisation call, before you commit.
A focused session to pressure-test the roadmap, weigh export vs local footprint, and plan execution — partners, structure and first moves.